drug discovery

InterAx partners with Lundbeck to identify better pharmaceutical compounds

InterAx Biotech AG, a spin-off of the Paul Scherrer Institute PSI and ETH Zurich, based at PARK INNOVAARE, is building a proprietary systems biology platform...

More details More details

Villigen – Boston – Villigen: Successful Business Trip for InterAx Biotech AG

InterAx Biotech AG participated in a “business boosting” week in Boston, USA, in June, 2016. As part of venturelab’s international program, 10 high...

More details

Tagesschau about PARK INNOVAARE

Together with leadXpro, SRF camera team visits the SwissFEL accelerator On the occasion of the official launch of Switzerland Innovation Park in Bern...

More details

leadXpro one year in operation: all goals achieved, and even more!

Today, leadXpro AG, one of PARK INNOVAARE’s residents, celebrates its first anniversary and breathtaking development as a company in its first year of...

More details

INNOVATION in PRACTICE 2017: technologies and products in focus

Innovation cannot be planned. But it can be achieved faster and more effectively when the innovation process is being managed properly. For the second...

More details

InterAx Biotech AG is strengthening its scientific advisory board

Scientific advisory boards set the bar for the quality of research and development performed in big pharma, medium biotech and small start-ups. Their excellence...

More details

InterAx Biotech has started a new collaboration

Collaborations speed up innovation. InterAx Biotech AG, a spin-off of the Paul Scherrer Institute (PSI) and ETH Zurich, based at PARK INNOVAARE, and Professor...

More details

NEW COLLABORATION ON A GPCR LEAD DISCOVERY PROJECT

Axxam SpA and leadXpro AG announce this week a collaboration for the discovery of novel small molecule lead compounds for a newly discovered GPCR involved...

More details

leadXpro about possibilities of new XFEL for applied research

Biotech startup leadXpro AG, at home at PARK INNOVAARE, applies serial crystallography among many other methods for structure-based drug design. It recently...

More details

LEADXPRO SCIENTISTS CHART THE FUTURE OF STRUCTURE BASED DRUG DISCOVERY

In a series of scientific publications leadXpro AG scientists explore the utility of cutting-edge X-ray technologies for the discovery of new therapeutics. Medicines...

More details

Two well-known techniques + new application field = breakthrough of the year

This fall, Dr. Tim Grüne from the Paul Scherrer Institute (PSI) together with Crystallise! AG published the results of their joint project, presenting...

More details

InterAx raises CHF 3 Mio for the commercialization of its systems biology platform

InterAx Biotech AG is a spin off from the ETH Zürich and Paul Scherrer Institute (PSI). The company assists GPCR drug candidate design and selection by...

More details
Subscribe to drug discovery